Talphera (TLPH) Competitors $0.94 -0.06 (-5.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.94 0.00 (0.00%) As of 09/12/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. INKT, MGX, OSTX, ALGS, PRLD, ARTV, VNRX, CLNN, IMMX, and VTVTShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include MiNK Therapeutics (INKT), Metagenomi (MGX), OS Therapies (OSTX), Aligos Therapeutics (ALGS), Prelude Therapeutics (PRLD), Artiva Biotherapeutics (ARTV), VolitionRx (VNRX), Clene (CLNN), Immix Biopharma (IMMX), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Its Competitors MiNK Therapeutics Metagenomi OS Therapies Aligos Therapeutics Prelude Therapeutics Artiva Biotherapeutics VolitionRx Clene Immix Biopharma vTv Therapeutics Talphera (NASDAQ:TLPH) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations. Do institutionals and insiders believe in TLPH or INKT? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 3.2% of Talphera shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to TLPH or INKT? In the previous week, Talphera had 4 more articles in the media than MiNK Therapeutics. MarketBeat recorded 6 mentions for Talphera and 2 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.45 beat Talphera's score of 0.27 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Talphera Neutral MiNK Therapeutics Positive Do analysts prefer TLPH or INKT? Talphera presently has a consensus target price of $5.00, indicating a potential upside of 431.91%. MiNK Therapeutics has a consensus target price of $37.50, indicating a potential upside of 160.42%. Given Talphera's stronger consensus rating and higher possible upside, equities analysts plainly believe Talphera is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility & risk, TLPH or INKT? Talphera has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Is TLPH or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -152.38% -64.32% MiNK Therapeutics N/A N/A -227.24% Which has higher earnings & valuation, TLPH or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Talphera. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$650K29.68-$13M-$0.40-2.35MiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.00 SummaryTalphera beats MiNK Therapeutics on 9 of the 14 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.44M$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-2.3523.8575.4125.98Price / Sales29.68529.66514.54181.13Price / CashN/A171.1637.5660.44Price / Book2.005.3712.156.29Net Income-$13M$32.95M$3.29B$271.07M7 Day Performance71.16%1.28%0.74%3.87%1 Month Performance117.34%6.09%4.81%4.88%1 Year Performance4.44%-2.15%60.57%26.12% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.0184 of 5 stars$0.94-5.6%$5.00+431.9%+4.4%$20.44M$650K-2.3519Short Interest ↑Gap UpINKTMiNK Therapeutics3.6008 of 5 stars$15.74-0.6%$37.50+138.3%+89.1%$71.12MN/A-5.4630Positive NewsShort Interest ↓MGXMetagenomi2.8107 of 5 stars$1.86-0.2%$10.00+438.8%-30.9%$69.99M$52.29M-0.79236Positive NewsOSTXOS Therapies2.0702 of 5 stars$2.19-2.5%$18.00+723.8%-35.7%$69.11MN/A-2.76N/AAnalyst ForecastALGSAligos Therapeutics4.0039 of 5 stars$11.16+0.5%$50.00+348.0%-27.3%$68.57M$3.94M-0.5690Positive NewsAnalyst ForecastPRLDPrelude Therapeutics3.1829 of 5 stars$1.21-3.6%$4.00+232.0%-76.6%$68.20M$7M-0.73120Positive NewsARTVArtiva Biotherapeutics3.1337 of 5 stars$2.75-11.0%$17.00+518.2%-76.3%$67.79M$250K0.0081Positive NewsVNRXVolitionRx2.3154 of 5 stars$0.63+2.6%$3.50+458.2%-6.3%$67.46M$1.32M-1.7480Analyst ForecastGap UpHigh Trading VolumeCLNNClene3.1833 of 5 stars$6.58-0.8%$33.00+401.5%-8.5%$65.73M$340K-1.75100News CoverageAnalyst ForecastIMMXImmix Biopharma2.96 of 5 stars$2.28+4.8%$7.00+207.7%+15.8%$65.59MN/A-2.959News CoverageAnalyst ForecastShort Interest ↑VTVTvTv Therapeutics2.6222 of 5 stars$19.64+4.7%$35.50+80.8%+35.1%$64.63M$1.02M-6.499Positive NewsGap Up Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Metagenomi Alternatives OS Therapies Alternatives Aligos Therapeutics Alternatives Prelude Therapeutics Alternatives Artiva Biotherapeutics Alternatives VolitionRx Alternatives Clene Alternatives Immix Biopharma Alternatives vTv Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
